86 related articles for article (PubMed ID: 17682992)
1. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Calleri G; Lesioba O; Belloro S; Raiteri R; Di Perri G
Clin Infect Dis; 2007 Sep; 45(5):583-8. PubMed ID: 17682992
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
[TBL] [Abstract][Full Text] [Related]
3. A short course of pegylated interferon-alpha in acute HCV hepatitis.
Calleri G; Cariti G; Gaiottino F; De Rosa FG; Bargiacchi O; Audagnotto S; Quaglia S; De Blasi T; Romano P; Traverso A; Leo G; Carbone R; Del Mastro B; Tinelli M; Caramello P; Di Perri G
J Viral Hepat; 2007 Feb; 14(2):116-21. PubMed ID: 17244251
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon monotherapy for chronic hepatitis C.
Heathcote J; Zeuzem S
Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
[TBL] [Abstract][Full Text] [Related]
5. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users.
Grebely J; Raffa JD; Meagher C; Duncan F; Genoway KA; Khara M; McLean M; Mead A; Viljoen M; DeVlaming S; Fraser C; Conway B
J Gastroenterol Hepatol; 2007 Sep; 22(9):1519-25. PubMed ID: 17645460
[TBL] [Abstract][Full Text] [Related]
6. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.
Dalgard O; Bjøro K; Ring-Larsen H; Bjornsson E; Holberg-Petersen M; Skovlund E; Reichard O; Myrvang B; Sundelöf B; Ritland S; Hellum K; Frydén A; Florholmen J; Verbaan H;
Hepatology; 2008 Jan; 47(1):35-42. PubMed ID: 17975791
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
10. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
[TBL] [Abstract][Full Text] [Related]
11. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
12. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.
Zhao H; Kurbanov F; Wan MB; Yin YK; Niu JQ; Hou JL; Wei L; Wang GQ; Tanaka Y; Mizokami M; Si CW
Clin Infect Dis; 2007 Feb; 44(4):541-8. PubMed ID: 17243057
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
14. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.
Broers B; Helbling B; François A; Schmid P; Chuard C; Hadengue A; Negro F;
J Hepatol; 2005 Mar; 42(3):323-8. PubMed ID: 15791696
[TBL] [Abstract][Full Text] [Related]
15. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
16. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
19. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.
Wiegand J; Buggisch P; Boecher W; Zeuzem S; Gelbmann CM; Berg T; Kauffmann W; Kallinowski B; Cornberg M; Jaeckel E; Wedemeyer H; Manns MP;
Hepatology; 2006 Feb; 43(2):250-6. PubMed ID: 16440367
[TBL] [Abstract][Full Text] [Related]
20. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
